IL6 and Stroke: In 4,893 patients with AF in the RE-LY trial, raised IL-6 was independently associated with a two-fold risk of stroke or systemic embolism (Q4 vs. Q1, HR 2.03, 95% CI 1.27–3.26), adjusted for vascular risk factors.